m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis

Abstract

Background METTL3 is an RNA methyltransferase that mediates m 6 A modification and is implicated in mRNA biogenesis, decay, and translation. However, the biomechanism through which METTL3 regulates MALAT1-miR-1914-3p-YAP axis activity to induce NSCLC drug resistance and metastasis is not very clear. Methods The expression of mRNA was analyzed by qPCR assays. Protein levels were analyzed by western blotting and immunofluorescent staining. Cellular proliferation was detected by CCK8 assays. Cell migration and invasion were analyzed by wound healing and transwell assays, respectively. Promoter activities and gene transcription were analyzed by luciferase reporter assays. Finally, m 6 A modification was analyzed by MeRIP. Results METTL3 increased the m 6 A modification of YAP . METTL3, YTHDF3, YTHDF1, and eIF3b directly promoted YAP translation through an interaction with the translation initiation machinery. Moreover, the RNA level of MALAT1 was increased due to a higher level of m 6 A modification mediated by METTL3. Meanwhile, the stability of MALAT1 was increased by METTL3/YTHDF3 complex. Additionally, MALAT1 functions as a competing endogenous RNA that sponges miR-1914-3p to promote the invasion and metastasis of NSCLC via YAP. Furthermore, the reduction of YAP m 6 A modification by METTL3 knockdown inhibits tumor growth and enhances sensitivity to DDP in vivo. Conclusion Results indicated that the m 6 A mRNA methylation initiated by METTL3 promotes YAP mRNA translation via recruiting YTHDF1/3 and eIF3b to the translation initiation complex and increases YAP mRNA stability through regulating the MALAT1-miR-1914-3p-YAP axis. The increased YAP expression and activity induce NSCLC drug resistance and metastasis.

Full text

We don’t show the text of a retracted or withdrawn paper. The record stays, so citations to it can be checked.

Cited by papers we hold 27

• METTL3 promotes chemoresistance in small cell lung cancer by inducing mitophagy · 2023
  No notice
• Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets · 2023
  No notice
• Insights into N6-methyladenosine and programmed cell death in cancer · 2022
  No notice
• Insight into the structure, physiological function, and role in cancer of m6A readers—YTH domain-containing proteins · 2022
  Not checked
• m6A modification: recent advances, anticancer targeted drug discovery and beyond · 2022
  No notice
• The Interaction Between N6-Methyladenosine Modification and Non-Coding RNAs in Gastrointestinal Tract Cancers · 2022
  Not checked
• Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma · 2022
  Not checked
• METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer · 2022
  No notice
• The role of m6A RNA methylation in cancer metabolism · 2022
  No notice
• Role of main RNA modifications in cancer: N6-methyladenosine, 5-methylcytosine, and pseudouridine · 2022
  No notice
• Recent advances of m6A methylation modification in esophageal squamous cell carcinoma · 2021
  Not checked
• The METTL3/MALAT1/PTBP1/USP8/TAK1 axis promotes pyroptosis and M1 polarization of macrophages and contributes to liver fibrosis · 2021
  No notice
• METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner · 2021
  No notice
• The m6A RNA methylation regulates oncogenic signaling pathways driving cell malignant transformation and carcinogenesis · 2021
  No notice
• The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities · 2021
  No notice
• RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases · 2021
  No notice
• ALKBH5-HOXA10 loop-mediated JAK2 m6A demethylation and cisplatin resistance in epithelial ovarian cancer · 2021
  No notice
• N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer · 2021
  No notice
• METTL3 May Regulate Testicular Germ Cell Tumors Through EMT and Immune Pathways · 2020
  Not checked
• The potential role of RNA N6-methyladenosine in Cancer progression · 2020
  No notice

and 7 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.